Search Results - V. S. Sygyrta

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    What do we know about the possibility of predicting the potential efficacy and safety of methotrexate, by measuring the concentration of its metabolites in rheumatoid arthritis?

    What do we know about the possibility of predicting the potential efficacy and safety of methotrexate, by measuring the concentration of its metabolites in rheumatoid arthritis? by G. I. Gridneva, E. S. Aronova, V. S. Sygyrta, A. V. Kudryavtseva, K. S. Nurbaeva

    Published 2020-09-01
    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    Arthritis as a clinical manifestation of antineutrophil cytoplasmic antibody-associated systemic vasculitis: diagnostic difficulties

    Arthritis as a clinical manifestation of antineutrophil cytoplasmic antibody-associated systemic vasculitis: diagnostic difficulties by T. V. Beketova, V. S. Sygyrta, N. V. Chichasova, N. F. Frolova, E. S. Stolyarevich, O. N. Kotenko

    Published 2018-06-01
    Get full text
    Article

    Save to List
    Saved in:
  3. 3
    Therapeutic drug monitoring of methotrexate and its metabolites in the red blood cells and mononuclear cells of patients with rheumatoid arthritis

    Therapeutic drug monitoring of methotrexate and its metabolites in the red blood cells and mononuclear cells of patients with rheumatoid arthritis by G. I. Gridneva, Yu. V. Muravyev, N. V. Baimeeva, V. S. Sygyrta, S. I. Glukhova, I. A. Guseva, E. Yu. Samarkina, E. S. Aronova, A. V. Kudryavtseva

    Published 2020-11-01
    Get full text
    Article

    Save to List
    Saved in:

Search Tools: